WASHINGTON – Swiss pharmaceutical maker Novartis AG will stop selling a drug to relieve constipation after it was linked to a higher chance of heart attack, stroke and worsening heart chest pain that ...

Novartis said Friday it has pulled its irritable bowel treatment Zelnorm (tegaserod maleate) off the US market after new clinical data showed an increased risk of cardiovascular events in patients ...

The FDA has agreed to permit limited use of Novartis’ Zelnorm (tegaserod maleate) by some patients through a restricted access program, following the drug’s voluntary withdrawal over cardiovascular ...

High-profile, quick-growing IBS drug shelved because of cardio risks. FDA has asked Novartis to pull Zelnorm (tegaserod) from the market five years after its approval, eliciting a swift and surprised ...

Novartis suspends US marketing and sales of Zelnorm(R) in response to request from FDA Retrospective analysis of pooled clinical trial data shows numerical imbalance in cardiovascular events in ...

Alfasigma USA Inc., which has a commercial hub in Bedminster, announced on Monday it has acquired the brand Zelnorm (tegaserod), a prescription pharmaceutical treatment for irritable bowel syndrome ...

Having restricted its use last year, Novartis has now served notice that it intends to take its irritable bowel syndrome off the US market completely. Having restricted its use last year, Novartis has ...

Novartis pulled bowel drug Zelnorm from U.S. shelves on Friday at the request of regulators because clinical trial data indicated a possible link to heart attacks and strokes. The move is a body blow ...

Dear Dr. Gott: I love your column. It’s been very beneficial to my family in many ways. I took Zelnorm over a year ago, until my doctor said the Food and Drug Administration had taken it off the ...

LOUISVILLE, Ken., April 1, 2019 /PRNewswire/ -- US WorldMeds has announced that Sloan Pharma, S.a.r.l., a subsidiary of US WorldMeds Holdings, LLC, has received approval from the U.S. Food and Drug ...

Novartis has notified the FDA that Zelnorm (tegaserod maleate) will no longer be available under a treatment investigational New Drug Application (T-IND) protocol to treat irritable bowel syndrome ...

Novartis ' Zelnorm, approved by U.S. regulators in July, could well reach annual sales of $1 billion or more. But in order for that to happen, Novartis has to convince gun-shy doctors that the drug is ...